# Max Healthcare Institute (NSE: MAXHEALTH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MAXHEALTH · Pivot · prices to 22 Oct 2026

Max Healthcare Institute (NSE: MAXHEALTH) closed at ₹804.80 on 22 Oct 2026, down 1.54% on the day. With a market capitalisation of ₹78,327 Cr, it ranks 137th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 54.6× trailing earnings, against a return on equity of 13.4% in FY26. Over the past year the share price has fallen 30.6%. Its 52-week range is ₹801.05 (22 Oct 2026) to ₹1,221.90 (23 Oct 2025); the last close is 34.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,143 Cr (+12.2% year on year) and net profit ₹342 Cr (+7.3%), on a consolidated basis. Promoters held 23.71% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹804.80 |
| Market cap | ₹78,327 Cr |
| P/E (trailing) | 54.6 |
| ROE | 13.4% (FY26) |
| ROCE | 13.0% (FY26) |
| Debt to equity | 0.27 |
| 52-week high | ₹1,221.90 (23 Oct 2025) |
| 52-week low | ₹801.05 (22 Oct 2026) |
| 1-year return | −30.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹2,143 Cr | +12.2% | ₹342 Cr | +7.3% | ₹3.52 |
| Q3 FY26 | ₹2,068 Cr | +10.7% | ₹301 Cr | +26.0% | ₹3.10 |
| Q2 FY26 | ₹2,135 Cr | +25.1% | ₹491 Cr | +74.3% | ₹5.05 |
| Q1 FY26 | ₹2,028 Cr | +31.4% | ₹308 Cr | +30.3% | ₹3.17 |
| Q4 FY25 | ₹1,910 Cr | +34.2% | ₹319 Cr | +26.8% | ₹3.28 |
| Q3 FY25 | ₹1,868 Cr | +40.0% | ₹239 Cr | −17.5% | ₹2.46 |
| Q2 FY25 | ₹1,707 Cr | +25.3% | ₹282 Cr | +1.9% | ₹2.90 |
| Q1 FY25 | ₹1,543 Cr | +20.1% | ₹236 Cr | −1.6% | ₹2.43 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7,028 Cr | ₹1,076 Cr |
| FY24 | ₹5,406 Cr | ₹1,058 Cr |
| FY23 | ₹4,563 Cr | ₹1,104 Cr |
| FY22 | ₹3,931 Cr | ₹605 Cr |
| FY21 | ₹2,505 Cr | −₹115 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 23.71%
- Foreign institutions: 41.78%
- Domestic institutions: 29.96%
- Non-institutions: 4.56%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,236.20 | ₹1,03,183 Cr | — | — |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,236.60 | ₹92,371 Cr | 48.4 | — |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,571.30 | ₹90,409 Cr | 26 | — |
| [Lupin](https://app.pivotnow.in/stock/LUPIN) | ₹1,929.60 | ₹88,228 Cr | 16.6 | — |
| [Glenmark Pharmaceuticals](https://app.pivotnow.in/stock/GLENMARK) | ₹2,196.40 | ₹61,983 Cr | 45.5 | — |
| [Alkem Laboratories](https://app.pivotnow.in/stock/ALKEM) | ₹4,972.00 | ₹59,448 Cr | 25.8 | — |

## Questions and answers

### What is the share price of Max Healthcare Institute today?

Max Healthcare Institute (NSE: MAXHEALTH) last closed at ₹804.80 on 22 Oct 2026. Its 52-week high is ₹1,221.90 and its 52-week low is ₹801.05.

### What is the market cap of Max Healthcare Institute?

Max Healthcare Institute's market capitalisation is ₹78,327 Cr (₹78,327 Cr) at the 22 Oct 2026 close, ranking 137th among the NSE companies Pivot tracks.

### What is the P/E ratio of Max Healthcare Institute?

Max Healthcare Institute trades at a trailing P/E of 54.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.

### What is the ROE and ROCE of Max Healthcare Institute?

Return on equity was 13.4% in FY26 and return on capital employed was 13.0% in FY26 (consolidated figures).

### Is Max Healthcare Institute a debt-free company?

No. Max Healthcare Institute's debt-to-equity ratio was 0.27 in FY26, with total debt of ₹2,439 Cr.

### What were Max Healthcare Institute's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Max Healthcare Institute reported revenue of ₹2,143 Cr, +12.2% year on year, and net profit of ₹342 Cr, +7.3% year on year.

### How has Max Healthcare Institute stock performed over the last year?

Max Healthcare Institute's share price has fallen 30.6% over the past year, −25.5% over three months and −24.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Max Healthcare Institute?

As of 30 Jun 2026: promoters 23.71%, foreign institutions 41.78%, domestic institutions 29.96%, non-institutions 4.56%.

### Who are Max Healthcare Institute's competitors?

The listed Pharma & Healthcare companies closest to Max Healthcare Institute by market cap are Dr. Reddy's Laboratories, Mankind Pharma, Aurobindo Pharma, Lupin, Glenmark Pharmaceuticals and Alkem Laboratories.

### Is Max Healthcare Institute a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Max Healthcare Institute's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MAXHEALTH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.